BACKGROUND: There is growing evidence that individual differences among depressed patients on electrophysiologic (EEG), neuroimaging, and neurocognitive measures are predictive of therapeutic response to antidepressant drugs. This study replicates prior findings of pretreatment differences between selective serotonin reuptake inhibitor (SSRI) responders and nonresponders in EEG alpha power or asymmetry and examines whether these differences normalize or are stable after treatment. METHODS: Resting EEG (eyes open and closed) was recorded from 28 electrodes (nose reference) in 18 depressed patients when off medication and at the end of 12 weeks of fluoxetine treatment. Clinical response was assessed by an independent rater with the Clinical Global Impression Improvement scale. The EEG data were also obtained for 18 healthy adults matched to patients in gender and age. RESULTS: Treatment responders had greater alpha power compared with nonresponders and healthy control subjects, with largest differences at occipital sites where alpha was largest. There were also differences in alpha asymmetry between responders and nonresponders at occipital sites. Responders showed greater alpha (less activity) over right than left hemisphere, whereas nonresponders tended to show the opposite asymmetry. Neither alpha power nor asymmetry changed after treatment, and test-retest correlations were high, particularly for alpha power. Alpha power and asymmetry showed reasonable positive predictive value but less negative predictive value. CONCLUSIONS: The findings confirm reports of alpha differences between antidepressant responders and nonresponders and raise hopes for developing EEG tests for selecting effective treatments for patients. The stability of alpha power and asymmetry differences between SSRI responders and nonresponders after treatment suggests that they represent state-independent characteristics.
BACKGROUND: There is growing evidence that individual differences among depressedpatients on electrophysiologic (EEG), neuroimaging, and neurocognitive measures are predictive of therapeutic response to antidepressant drugs. This study replicates prior findings of pretreatment differences between selective serotonin reuptake inhibitor (SSRI) responders and nonresponders in EEG alpha power or asymmetry and examines whether these differences normalize or are stable after treatment. METHODS: Resting EEG (eyes open and closed) was recorded from 28 electrodes (nose reference) in 18 depressedpatients when off medication and at the end of 12 weeks of fluoxetine treatment. Clinical response was assessed by an independent rater with the Clinical Global Impression Improvement scale. The EEG data were also obtained for 18 healthy adults matched to patients in gender and age. RESULTS: Treatment responders had greater alpha power compared with nonresponders and healthy control subjects, with largest differences at occipital sites where alpha was largest. There were also differences in alpha asymmetry between responders and nonresponders at occipital sites. Responders showed greater alpha (less activity) over right than left hemisphere, whereas nonresponders tended to show the opposite asymmetry. Neither alpha power nor asymmetry changed after treatment, and test-retest correlations were high, particularly for alpha power. Alpha power and asymmetry showed reasonable positive predictive value but less negative predictive value. CONCLUSIONS: The findings confirm reports of alpha differences between antidepressant responders and nonresponders and raise hopes for developing EEG tests for selecting effective treatments for patients. The stability of alpha power and asymmetry differences between SSRI responders and nonresponders after treatment suggests that they represent state-independent characteristics.
Authors: G E Bruder; J W Stewart; C E Tenke; P J McGrath; P Leite; N Bhattacharya; F M Quitkin Journal: Biol Psychiatry Date: 2001-03-01 Impact factor: 13.382
Authors: Ian A Cook; Andrew F Leuchter; Melinda Morgan; Elise Witte; William F Stubbeman; Michelle Abrams; Susan Rosenberg; Sebastian H J Uijtdehaage Journal: Neuropsychopharmacology Date: 2002-07 Impact factor: 7.853
Authors: D Pizzagalli; R D Pascual-Marqui; J B Nitschke; T R Oakes; C L Larson; H C Abercrombie; S M Schaefer; J V Koger; R M Benca; R J Davidson Journal: Am J Psychiatry Date: 2001-03 Impact factor: 18.112
Authors: J Gallinat; R Bottlender; G Juckel; A Munke-Puchner; G Stotz; H J Kuss; P Mavrogiorgou; U Hegerl Journal: Psychopharmacology (Berl) Date: 2000-03 Impact factor: 4.530
Authors: J J Dunkin; A F Leuchter; I A Cook; J E Kasl-Godley; M Abrams; S Rosenberg-Thompson Journal: J Affect Disord Date: 2000-10 Impact factor: 4.839
Authors: Sanjaya Saxena; Arthur L Brody; Matthew L Ho; Narineh Zohrabi; Karron M Maidment; Lewis R Baxter Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: L S Prichep; F Mas; E Hollander; M Liebowitz; E R John; M Almas; C M DeCaria; R H Levine Journal: Psychiatry Res Date: 1993-04 Impact factor: 3.222
Authors: Carlye B G Manna; Craig E Tenke; Nathan A Gates; Jürgen Kayser; Joan C Borod; Jonathan W Stewart; Patrick J McGrath; Gerard E Bruder Journal: Clin EEG Neurosci Date: 2010-10 Impact factor: 1.843
Authors: C E Tenke; J Kayser; L Miller; V Warner; P Wickramaratne; M M Weissman; G E Bruder Journal: Biol Psychol Date: 2013-08-30 Impact factor: 3.251
Authors: Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter Journal: J Psychiatr Res Date: 2020-02-26 Impact factor: 4.791
Authors: Craig E Tenke; Jürgen Kayser; Jorge E Alvarenga; Karen S Abraham; Virginia Warner; Ardesheer Talati; Myrna M Weissman; Gerard E Bruder Journal: Clin Neurophysiol Date: 2018-04-16 Impact factor: 3.708
Authors: Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff Journal: Am J Psychiatry Date: 2018-10-03 Impact factor: 18.112
Authors: Andrew F Leuchter; Ian A Cook; Steven P Hamilton; Katherine L Narr; Arthur Toga; Aimee M Hunter; Kym Faull; Julian Whitelegge; Anne M Andrews; Joseph Loo; Baldwin Way; Stanley F Nelson; Steven Horvath; Barry D Lebowitz Journal: Curr Psychiatry Rep Date: 2010-12 Impact factor: 5.285